NGS Chromosome Analysis: Next-Generation Genetic Screening for IVF

What Is NGS Chromosome Analysis in IVF?

Next-Generation Sequencing (NGS) represents a revolutionary advancement in genetic screening technology that has transformed the landscape of in vitro fertilization. At GynoLife IVF Center in North Cyprus, NGS chromosome analysis is used to evaluate embryos at the genetic level before transfer, identifying chromosomal abnormalities that could lead to implantation failure, miscarriage, or genetic disorders in offspring.

Unlike older genetic screening methods, NGS provides comprehensive analysis of all 23 pairs of chromosomes with unmatched precision and reliability. This technology reads the entire genetic blueprint of embryonic cells, detecting even subtle chromosomal imbalances that previous techniques might miss. The result is a more informed embryo selection process that significantly improves IVF outcomes.

NGS has become the gold standard for preimplantation genetic testing (PGT) worldwide, replacing older technologies such as array comparative genomic hybridization (aCGH) and fluorescence in situ hybridization (FISH). Its superior resolution, higher throughput, and cost-effectiveness make it the preferred choice for modern fertility clinics committed to delivering the best possible results.

How NGS Technology Works

Understanding the science behind NGS helps patients appreciate the power and precision of this genetic screening tool.

The Biopsy Process

NGS analysis begins with a small biopsy of the embryo, typically performed at the blastocyst stage on day five or six of development. A skilled embryologist carefully removes three to five cells from the trophectoderm, the outer cell layer that will eventually form the placenta. This procedure does not harm the inner cell mass, which develops into the baby, and has been proven safe through decades of research and clinical practice.

DNA Amplification and Sequencing

The biopsied cells contain only a tiny amount of DNA, so the first step is whole genome amplification (WGA), which creates millions of copies of the DNA to provide sufficient material for analysis. The amplified DNA is then fragmented, tagged with molecular barcodes, and processed through the NGS sequencing platform.

The sequencer reads millions of short DNA fragments simultaneously, mapping them back to the reference human genome. Sophisticated bioinformatics software analyzes the data to determine the copy number of each chromosome, identifying any gains (trisomies) or losses (monosomies) across all 23 chromosome pairs.

Results Interpretation

The analysis produces a detailed report for each embryo, classifying it as euploid (normal chromosome count), aneuploid (abnormal chromosome count), or mosaic (a mixture of normal and abnormal cells). Our geneticists and fertility specialists review these results together to guide embryo selection decisions.

Benefits of NGS Screening for IVF Patients

NGS chromosome analysis offers numerous advantages that directly impact treatment success and patient experience.

Higher Implantation Rates

By selecting only chromosomally normal embryos for transfer, NGS dramatically increases the probability of successful implantation. Studies have shown that euploid embryo transfers achieve implantation rates exceeding 60 percent, compared to approximately 30-40 percent for unscreened embryos. This means fewer transfer attempts are needed to achieve pregnancy.

Reduced Miscarriage Risk

Chromosomal abnormalities are the leading cause of first-trimester miscarriage, accounting for approximately 50-70 percent of all pregnancy losses. NGS screening identifies aneuploid embryos before transfer, significantly reducing the risk of miscarriage and the emotional and physical toll it takes on patients.

Shorter Time to Pregnancy

By avoiding the transfer of chromosomally abnormal embryos that are unlikely to result in a healthy pregnancy, NGS helps patients achieve their goal faster. This translates to fewer treatment cycles, less medication, reduced costs, and less emotional stress over time.

Single Embryo Transfer Confidence

With NGS screening, clinicians can confidently recommend single embryo transfer (SET) knowing that the selected embryo has the best possible chance of success. This approach virtually eliminates the risk of twin or triplet pregnancies, which carry significantly higher risks for both mother and babies.

Detection of Structural Abnormalities

Advanced NGS platforms can detect not only whole chromosome gains and losses but also segmental aneuploidies, where only part of a chromosome is duplicated or deleted. These structural abnormalities, which could be missed by older screening methods, can cause significant developmental issues.

Who Should Consider NGS Screening?

While any IVF patient can benefit from NGS chromosome analysis, it is particularly recommended for certain groups:

• Women over 35: The risk of chromosomal abnormalities increases significantly with maternal age. NGS helps identify the best embryos from a cohort that may include a higher proportion of aneuploid embryos.
• Patients with recurrent miscarriage: If you have experienced two or more pregnancy losses, NGS can determine whether chromosomal factors are contributing to the problem.
• Couples with previous IVF failures: Repeated implantation failure may be caused by the inadvertent transfer of aneuploid embryos. NGS screening can break this cycle.
• Known chromosomal translocation carriers: Patients who carry balanced translocations produce a higher proportion of unbalanced embryos. NGS identifies which embryos are safe to transfer.
• Carriers of sex-linked genetic disorders: PGD can help identify embryos unaffected by an inherited condition, reducing the risk of passing a serious disease to a child.
• Couples wanting to minimize treatment cycles: By maximizing the chance of success with each transfer, NGS reduces the total number of cycles needed.

NGS vs. Older Genetic Screening Methods

To appreciate the advantages of NGS, it helps to understand how it compares to previous technologies.

NGS vs. FISH

Fluorescence in situ hybridization (FISH) was the first widely used PGT method but could only analyze a limited number of chromosomes, typically five to twelve. NGS screens all 23 pairs simultaneously with higher accuracy, making FISH largely obsolete for routine PGT screening.

NGS vs. aCGH

Array comparative genomic hybridization (aCGH) represented a significant improvement over FISH by analyzing all chromosomes. However, NGS offers several advantages over aCGH, including higher resolution for detecting segmental abnormalities, better detection of mosaicism, the ability to process multiple samples simultaneously, and lower per-sample costs.

NGS vs. qPCR

Quantitative polymerase chain reaction (qPCR) is another screening method that analyzes all chromosomes. While effective, NGS provides superior resolution and can detect a broader range of abnormalities, including low-level mosaicism and small segmental changes.

The NGS Screening Process at GynoLife IVF Center

At GynoLife, we have integrated NGS screening seamlessly into our IVF protocols to provide patients with the most advanced care available.

Treatment Timeline

The typical timeline for an IVF cycle with NGS screening follows these stages:

• Days 1-12: Ovarian stimulation with fertility medications to produce multiple eggs.
• Day 12-14: Egg retrieval procedure under light sedation.
• Day 0: Fertilization using ICSI (intracytoplasmic sperm injection) for optimal results.
• Days 1-5: Embryo culture in our advanced laboratory incubators.
• Day 5-6: Trophectoderm biopsy of blastocyst-stage embryos.
• Days 6-13: NGS analysis at the genetics laboratory (results typically available within 7-10 days).
• Embryo vitrification: All biopsied embryos are vitrified (flash-frozen) while awaiting results.
• Frozen embryo transfer: Euploid embryos are transferred in a subsequent cycle after endometrial preparation.

Our Laboratory Standards

GynoLife IVF Center maintains the highest laboratory standards for NGS screening. Our embryology team has extensive experience in blastocyst biopsy, and our genetics partners use validated NGS platforms with rigorous quality control protocols. Every result is reviewed by experienced geneticists before being reported to the clinical team.

Understanding Your NGS Results

When you receive your NGS results, each embryo will be classified into one of the following categories:

Euploid (Normal)

These embryos have the correct number of chromosomes (46, or 23 pairs) and are suitable for transfer. Euploid embryos have the highest probability of successful implantation and healthy pregnancy.

Aneuploid (Abnormal)

These embryos have one or more chromosome abnormalities, such as an extra chromosome (trisomy) or a missing chromosome (monosomy). Aneuploid embryos are generally not recommended for transfer as they are unlikely to implant successfully or may result in miscarriage.

Mosaic

Mosaic embryos contain a mixture of normal and abnormal cells. The clinical significance of mosaicism is still being studied, but low-level mosaic embryos may be considered for transfer when no euploid embryos are available, after thorough counseling about the potential risks and outcomes.

Combining NGS with Other Advanced Technologies

At GynoLife IVF Center, NGS screening can be combined with other cutting-edge technologies to further optimize outcomes:

• EmbryoScope time-lapse monitoring: Continuous observation of embryo development provides additional morphological data to complement genetic information.
• ERA (Endometrial Receptivity Analysis): Identifying the optimal window of implantation ensures that genetically normal embryos are transferred at the best possible time.
• PGT-M for monogenic disorders: In addition to chromosome screening, NGS can be configured to test for specific single-gene disorders such as cystic fibrosis, sickle cell disease, or thalassemia.

Frequently Asked Questions About NGS Screening

Is the embryo biopsy safe?

Yes. Trophectoderm biopsy has been performed for over two decades with extensive safety data. Studies consistently show that biopsied embryos develop normally and that children born after PGT have the same health outcomes as those conceived without biopsy.

Does NGS guarantee a healthy baby?

NGS screens for chromosome number abnormalities and large structural changes but does not test for every possible genetic condition. It significantly reduces the risk of chromosomal disorders and miscarriage but cannot guarantee a completely healthy outcome, as no prenatal test can.

What if all my embryos are abnormal?

This outcome, while disappointing, actually provides valuable information. It may explain previous IVF failures and helps your medical team adjust the treatment strategy. Options may include additional IVF cycles, changes to stimulation protocols, or consideration of donor gametes.

How much does NGS screening add to the cost of IVF?

At GynoLife IVF Center, we offer NGS screening at competitive prices that represent excellent value given the significant improvement in success rates. The cost is a fraction of what patients would pay at clinics in Western Europe or the United States.

Start Your Journey with Confidence

NGS chromosome analysis represents the pinnacle of genetic screening technology in reproductive medicine. By incorporating this powerful tool into your IVF treatment at GynoLife IVF Center, you can approach your fertility journey with greater confidence, knowing that every possible step has been taken to maximize your chances of a healthy pregnancy.

Our team of fertility specialists, embryologists, and genetic counselors is ready to guide you through every aspect of NGS screening and help you make informed decisions about your treatment.

Ready to learn more about how NGS can improve your IVF success? Schedule your free consultation with GynoLife IVF Center today.